Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium
Zealand Pharma announces its participation in the Goldman Sachs 11th Annual Biotech Symposium on September 7, 2021. The event will feature members of Zealand's senior management team discussing the company’s advancements in peptide-based medicines. Zealand Pharma has successfully brought V-Go® and Zegalogue® to market and continues to develop additional drug candidates. With a strong presence in both Copenhagen and the U.S., the company is positioned for further growth and collaboration.
- None.
- None.
Company announcement – No. 55 / 2021
Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium
Copenhagen, DK and Boston, MA, U.S. August 31, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 11th Annual Biotech Symposium:
| Goldman Sachs 11th Annual Biotech Symposium |
| Date: Tuesday, September 7, 2021 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. To support these two marketed products Zealand built a dedicated sales force in the United States and has established itself as a fully integrated biotechnology company. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Claudia Styslinger |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What event is Zealand Pharma participating in?
When is Zealand Pharma attending the Goldman Sachs Biotech Symposium?
What is Zealand Pharma known for?
What products has Zealand Pharma brought to market?
Where is Zealand Pharma headquartered?
What are some key milestones for Zealand Pharma?
